---
title: "Ionis stock has plunged 30%. Is it time to buy the beaten-down stock?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295927286.md"
description: "A drug that didn't meet expectations in a trial is to blame."
datetime: "2026-08-14T11:30:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295927286.md)
  - [en](https://longbridge.com/en/news/295927286.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295927286.md)
generator: "portal-rs"
---

# Ionis stock has plunged 30%. Is it time to buy the beaten-down stock?

A drug that didn't meet expectations in a trial is to blame.

### Related Stocks

- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday](https://longbridge.com/en/news/296352846.md)
- [Southern Copper (NYSE:SCCO) Shares Up 8.3%  - Still a Buy?](https://longbridge.com/en/news/296638179.md)
- [Is it Time to Begin Accumulating Natural Gas?](https://longbridge.com/en/news/295953555.md)
- [Meet the Newest Stock in the S&P 500. It Soared 424% Since Its 2024 IPO, and It's a Buy Right Now, According to Wall Street](https://longbridge.com/en/news/296149360.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**